In conclusion, our study identified ATF5 as a promoter of neuroblastoma metastasis and CP-d/n-ATF5 as an antimetastatic therapeutic agent with the potential to improve the clinical outcomes of metastatic neuroblastoma. This evidence concerns the gene CPD and neuroblastoma.